By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Jazz Pharmaceuticals 

Corporate Headquarters
Fourth Floor, Connaught House

One Burlington Road
Dublin    4  Ireland
Phone: 353-1-634-7800 Fax: 353-1-634-7850


Jazz Pharmaceuticals plc is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. We have a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. We also support commercial products in therapeutic areas where we can meaningfully address serious medical needs.

As part of our unwavering commitment to improve patients’ lives, we continue to expand our commercial product portfolio and our research and development pipeline in therapeutic areas that can leverage our unique expertise. We do this through a growth strategy of growing sales of the existing products in our portfolio; acquiring additional differentiated products that are on the market or product candidates that are in late-stage development; and pursuing focused development of a pipeline of post-discovery differentiated product candidates.

Our Culture

We have a strong patient-focused culture at Jazz Pharmaceuticals that our employees believe in and pursue every day. It is clearly identified through our mission, vision and core values. Each member of our team makes integral contributions and is working toward a common goal to improve patients' lives. Everything we do at Jazz Pharmaceuticals is focused on three things:
• Putting patients first
• Being a great place to work
• Living our core values — integrity, collaboration, passion, pursuit of excellence and innovation

Key Statistics

Ownership: Public

Web Site: Jazz Pharma
Symbol: JAZZ


Company News
Jazz Pharma (JAZZ) Announces Positive Results From The Phase III TONES 3 And TONES 4 Studies Of JZP-110 In Patients With Obstructive Sleep Apnea 3/20/2017 7:36:23 AM
Jazz Pharma (JAZZ) Announces First Patient Enrolled In Phase III Clinical Study Evaluating JZP-258 For The Treatment Of Cataplexy And Excessive Daytime Sleepiness In Narcolepsy 3/16/2017 6:35:19 AM
Jazz Pharma (JAZZ) Announces Full Year And Fourth Quarter 2016 Financial Results 3/1/2017 9:50:15 AM
Jazz Pharma (JAZZ) To Report 2016 Fourth Quarter And Full Year Financial Results On February 28, 2017 2/15/2017 8:11:14 AM
Jazz Pharma (JAZZ) Announces First Patient Enrolled In Phase II Clinical Study Evaluating JZP-110 For Excessive Sleepiness In Parkinson's Disease 2/9/2017 6:48:23 AM
FDA Lashes Out at Jazz Pharma (JAZZ) CMO for Continued Regulatory Violations 1/27/2017 6:09:20 AM
Jazz Pharma (JAZZ) Release: Company Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating Defibrotide For The Potential Prevention Of VOD In High Risk Patients 1/18/2017 6:14:04 AM
Jazz Pharma (JAZZ) Announces That Patient Enrollment Is Complete For The Phase 3 Study Of JZP-110 Evaluating Excessive Sleepiness In Narcolepsy 11/29/2016 6:33:58 AM
Jazz Pharma (JAZZ) Announces Third Quarter 2016 Financial Results 11/9/2016 1:28:05 PM
Jazz Pharma (JAZZ)'s 841% Price Increase On A Sleep Drug Could Attract Attention From Capitol Hill 11/3/2016 6:47:59 AM